Acute Lymphoblastic Leukemia, in Relapse Clinical Trials in Beijing, Beijing Municipality
7 recruitingBeijing, Beijing Municipality, China
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting
Not Applicable
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital353 enrolled1 locationNCT06343090
Recruiting
Phase 1
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic Leukemia
Beijing GoBroad Hospital48 enrolled1 locationNCT06326008
Recruiting
Not Applicable
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital213 enrolled1 locationNCT06389305
Recruiting
Phase 1Phase 2
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 1Phase 2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in Relapse
Essen Biotech75 enrolled1 locationNCT06213636